Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

MediSpectra Begins Luma Trial
Oct 2002
LEXINGTON, Mass., Oct. 11 -- Medical device company MediSpectra Inc. said it has begun enrolling patients in a major clinical study of its cervical imaging system, Luma, at thirteen sites in the US. The study of 2200 women with abnormal Pap smears will compare the performance of Luma as an adjunct to colposcopy (the current method for evaluating Pap smear results) to colposcopy alone.

In a 12-second optical scan, Luma collects biochemical and cellular characteristics from a patient's cervical tissue. Areas of the cervix with high-grade precancerous lesions are then identified and displayed on a color video image. The clinician uses the image of high-grade disease areas in combination with colposcopy to select locations to biopsy.

In a preceding 604-patient pilot study conducted at six medical centers, an analysis of the data suggested Luma can detect 31 percent more high-grade precancerous lesions than colposcopy, MediSpectra said.

MediSpectra recently completed a $13 million round in venture capital investment, bringing the total amount raised to $55 million. The company said it anticipates submitting the clinical trial results to the US Food and Drug Administration for product approval.

For more information, visit:

News & Features

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.